Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367846 | 0.85 | HPGD (0.54) | HPGDHTTCYP19A1SMN1; SMN2CYP1A2 | |
| SCHEMBL795210 | 0.84 | HPGD (0.68) | HPGDHTTCYP19A1SMN1; SMN2CYP1A2 | |
| SCHEMBL2367880 | 0.83 | CYP19A1 (0.53) | HPGDHTTCYP19A1SMN1; SMN2CYP1A2 | |
| SCHEMBL2368342 | 0.83 | POLB (0.53) | HPGDPTGER4HTTCYP19A1SMN1; SMN2 | |
| SCHEMBL1923196 | 0.82 | HPGD (0.48) | HPGDHTTSMN1; SMN2KLKB1 | |
| SCHEMBL17351879 | 0.81 | ALOX15 (0.56) | HPGDSMN1; SMN2CYP1A2ALDH1A1POLB | |
| SCHEMBL2367657 | 0.80 | GRN (0.49) | HPGDHTTCYP19A1SMN1; SMN2CYP1A2 | |
| SCHEMBL18320967 | 0.80 | HPGD (0.48) | HPGDHTTCYP19A1SMN1; SMN2CYP1A2 | |
| SCHEMBL2367593 | 0.78 | HPGD (0.53) | HPGDPTGER4CYP19A1SMN1; SMN2CYP1A2 | |
| SCHEMBL2368340 | 0.78 | HPGD (0.50) | HPGDHTTCYP19A1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051281-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2368887-B1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20130281499-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2013-10-24 | — | — | US | disclosed |
| US-8486977-B2 | 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2368887-A1 | 1, 2, 3-triazole derivatives for use as stearoyl-COA desaturase inhibitors | Glaxosmithkline LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, FASN | HPGD 592/4885COPS5 2335/4885PTGER4 1978/4885 |
| US-20130281499-A1 | COMPOUNDS | CYP11B2, SCD, CYP11B1 | HPGD 719/4885COPS5 2104/4885PTGER4 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.